Correlation Between Shiftide Activity and HIV-1 Integrase Inhibition by a Peptide Selected from a Combinatorial Library

Journal of Molecular Biology

Volumn 376, Issue 4, 2008, Pages 971-982

  Armon Omer, Ayelet ^a   Levin, Aviad ^a   Hayouka, Zvi ^a   Butz, Karin ^b   Hoppe Seyler, Felix ^b   Loya, Shoshana ^c   Hizi, Amnon ^c   Friedler, Assaf ^a   Loyter, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

fluorescence anisotropy; HIV 1; integrase; synthetic peptides; yeast two hybrid

Indexed keywords

AMINO ACID; INTEGRASE; PEPTIDE DERIVATIVE; VIRUS ENZYME;

ANISOTROPY; ARTICLE; CELL CULTURE; COMBINATORIAL LIBRARY; CORRELATION ANALYSIS; DNA BINDING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; GEL FILTRATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; VIRUS REPLICATION; YEAST;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 39049115937     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.11.095     Document Type: Article

References (43)

1. Sherman M.P., and Greene W.C. Slipping through the door: HIV entry into the nucleus. Microbes Infect. 4 (2002) 67-73
2. Pommier Y., Johnson A.A., and Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4 (2005) 236-248
3. Hazuda D.J., Young S.D., Guare J.P., Anthony N.J., Gomez R.P., Wai J.S., et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305 (2004) 528-532
4. Lataillade M., and Kozal M.J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDs 20 (2006) 489-501
5. Markowitz M., Morales-Ramirez J.O., Nguyen B.Y., Kovacs C.M., Steigbigel R.T., Cooper D.A., et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquired Immune Defic. Syndr. 43 (2006) 509-515
6. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369 (2007) 1261-1269
7. Cahn P., and Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 369 (2007) 1235-1236
8. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., and Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl Acad. Sci. USA 102 (2005) 17308-17313
9. Hayouka Z., Rosenbluh J., Levin A., Loya S., Lebendiker M., Veprintsev D., et al. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Natl Acad. Sci. USA 104 (2007) 8316-8321
10. Chen A., Weber I.T., Harrison R.W., and Leis J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends. J. Biol. Chem. 281 (2006) 4173-4182
11. Deprez E., Tauc P., Leh H., Mouscadet J.F., Auclair C., and Brochon J.C. Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy. Biochemistry 39 (2000) 9275-9284
12. Deprez E., Tauc P., Leh H., Mouscadet J.F., Auclair C., Hawkins M.E., et al. DNA binding induces dissociation of the multimeric form of HIV-1 integrase: a time-resolved fluorescence anisotropy study. Proc. Natl Acad. Sci. USA 98 (2001) 10090-10095
13. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., et al. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 33 (2005) 977-986
14. Guiot E., Carayon K., Delelis O., Simon F., Tauc P., Zubin E., et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 281 (2006) 22707-22719
15. Zhao L., O'Reilly M.K., Shultz M.D., and Chmielewski J. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg. Med. Chem. Lett. 13 (2003) 1175-1177
16. Butz K., Denk C., Ullmann A., Scheffner M., and Hoppe-Seyler F. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl Acad. Sci. USA 97 (2000) 6693-6697
17. Hoppe-Seyler F., Crnkovic-Mertens I., Tomai E., and Butz K. Peptide aptamers: specific inhibitors of protein function. Curr. Mol. Med. 4 (2004) 529-538
18. Tomai E., Butz K., Lohrey C., von Weizsacker F., Zentgraf H., and Hoppe-Seyler F. Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes. J. Biol. Chem. 281 (2006) 21345-21352
19. de Soultrait V.R., Caumont A., Parissi V., Morellet N., Ventura M., Lenoir C., et al. A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. J. Mol. Biol. 318 (2002) 45-58
20. Armon-Omer A., Graessmann A., and Loyter A. A synthetic peptide bearing the HIV-1 integrase 161-173 amino acid residues mediates active nuclear import and binding to importin alpha: characterization of a functional nuclear localization signal. J. Mol. Biol. 336 (2004) 1117-1128
21. Gleenberg I.O., Herschhorn A., and Hizi A. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J. Mol. Biol. 369 (2007) 1230-1243
22. Oz Gleenberg I., Avidan O., Goldgur Y., Herschhorn A., and Hizi A. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J. Biol. Chem. 280 (2005) 21987-21996
23. Craigie R., Mizuuchi K., Bushman F.D., and Engelman A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 19 (1991) 2729-2734
24. Hwang Y., Rhodes D., and Bushman F. Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation. Nucleic Acids Res. 28 (2000) 4884-4892
25. Rosenbluh J., Hayouka Z., Loya S., Levin A., Armon-Omer A., Britan E., et al. Interaction between HIV-1 Rev and Integrase proteins: a basis for the development of anti-HIV peptides. J. Biol. Chem. 282 (2007) 15743-15753
26. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
27. Rigourd M., Lanchy J.M., Le Grice S.F., Ehresmann B., Ehresmann C., and Marquet R. Inhibition of the initiation of HIV-1 reverse transcription by 3′-azido-3′-deoxythymidine. Comparison with elongation. J. Biol. Chem. 275 (2000) 26944-26951
28. Pannecouque C., Pluymers W., Van Maele B., Tetz V., Cherepanov P., De Clercq E., et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 12 (2002) 1169-1177
29. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., and De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc. Natl Acad. Sci. USA 85 (1988) 6132-6136
30. + cells. Science 240 (1988) 646-649
31. Nakashima H., Yoshida O., Baba M., De Clercq E., and Yamamoto N. Anti-HIV activity of dextran sulphate as determined under different experimental conditions. Antiviral Res. 11 (1989) 233-246
32. Maroun R.G., Gayet S., Benleulmi M.S., Porumb H., Zargarian L., Merad H., et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40 (2001) 13840-13848
33. Li H.Y., Zawahir Z., Song L.D., Long Y.Q., and Neamati N. Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. J. Med. Chem. 49 (2006) 4477-4486
34. Rosenbluh J., Kapelnikov A., Shalev D.E., Rusnati M., Bugatti A., and Loyter A. Positively charged peptides can interact with each other, as revealed by solid phase binding assays. Anal. Biochem. 352 (2006) 157-168
35. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74 (2000) 8358-8367
36. Armon-Omer, A., Rosenbluh, J., Melamed-Book, N., Graessmann, A., Waigmann, E., Loyter, A. (2007). Nuclear import of HIV integrase in yeast is mediated by a specific NLS and via importin alpha. Biochemistry. Submitted
37. Gietz D., St. Jean A., Woods R.A., and Schiestl R.H. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20 (1992) 1425
38. Kohler F., Cardon G., Pohlman M., Gill R., and Schider O. Enhancement of transformation rates in higher plants by low-dose irradiation: are DNA repair systems involved in incorporation of exogenous DNA into the plant genome?. Plant Mol. Biol. 12 (1989) 189-199
39. Heinzinger N.K., Bukinsky M.I., Haggerty S.A., Ragland A.M., Kewalramani V., Lee M.A., et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl Acad. Sci. USA 91 (1994) 7311-7315
40. Jenkins T.M., Engelman A., Ghirlando R., and Craigie R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 271 (1996) 7712-7718
41. Marchand C., Neamati N., and Pommier Y. In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol. 340 (2001) 624-633
42. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl Acad. Sci. USA 99 (2002) 937-942
43. Yamamoto N., Tanaka C., Wu Y., Chang M.O., Inagaki Y., Saito Y., et al. Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes 32 (2006) 105-113